Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 18/20 | 0.53 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | TACR2 | P21452 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9935482 | 0.87 | CNR1 (0.49) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL9935434 | 0.87 | CNR1 (0.49) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL9931384 | 0.86 | CNR1 (0.72) | CNR1CNR2TACR2 | |
| SCHEMBL9973792 | 0.84 | CNR1 (0.74) | CNR1CNR2TACR2 | |
| SCHEMBL9935929 | 0.79 | CNR1 (0.41) | CNR1CNR2TACR2TACR1 | |
| SCHEMBL9932199 | 0.77 | CNR1 (0.60) | CNR1CNR2TACR2 | |
| SCHEMBL9931115 | 0.77 | CNR1 (0.60) | CNR1CNR2TACR2 | |
| SCHEMBL410983 | 0.77 | CNR1 (0.48) | CNR1 | |
| SCHEMBL412280 | 0.75 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL9978233 | 0.75 | CNR1 (0.46) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | CNR1 1065/4885CNR2 1642/4885TACR2 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.